All In Biotech

Free tool

FAERS Monitor: Sklice

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202736 or its brand name (Sklice, Ivermectin). Reports on generic versions are filed under their own applications.

Reports

3,499

Serious

1,942

56% of reports

Hospitalization

991

Death reported

329

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective644
  • off label use403
  • product use in unapproved indication286
  • pruritus172
  • headache165
  • fatigue125
  • asthenia121
  • nausea115
  • pyrexia113
  • diarrhoea102
  • strongyloidiasis102
  • vomiting102
  • rash94
  • pain93
  • dyspnoea90

Reports by year received

View as table
YearReports
20056
20063
20073
20087
200912
20103
201111
20126
201361
201465
201560
201647
2017212
2018269
2019219
2020201
2021387
2022350
2023295
2024326
2025525
2026431

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
strongyloidiasisSignal102405.1332.438,143
product use in unapproved indicationSignal2866.96.21,465
drug ineffectiveSignal6442.92.7876
off label useSignal4032.82.5473
pruritusSignal1722.72.3184
pyrexia1132.01.653
asthenia1211.91.655
headache1651.61.436
vomiting1021.31.17
rash941.31.16
fatigue1251.00.80
dyspnoea901.00.80
diarrhoea1020.90.80
pain930.90.71
nausea1150.90.72

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.